Full-Time
Posted on 7/19/2023
Direct-to-consumer DNA testing services
$240k - $360k/yr
Expert
Sunnyvale, CA, USA
Requires onsite presence in Sunnyvale, California for a minimum of three days per week.
Requires onsite presence in Sunnyvale, California for a minimum of three days per week.
Requires onsite presence in Sunnyvale, California for a minimum of three days per week.
23andMe offers direct-to-consumer DNA testing that provides individuals with insights into their ancestry, genetic traits, and potential health risks. Customers purchase a DNA testing kit, send in a saliva sample, and receive personalized genetic reports based on the analysis of their DNA. This service appeals to a wide range of people, from those curious about their family history to those wanting to understand their health predispositions. Unlike many competitors, 23andMe not only sells these kits but also offers subscription services for ongoing updates and insights based on new genetic research. Additionally, the company utilizes its large genetic database for research collaborations, which can lead to further revenue through partnerships with research institutions and pharmaceutical companies. The goal of 23andMe is to empower individuals with knowledge about their genetics while contributing to advancements in genetic research.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Sunnyvale, California
Founded
2006
Help us improve and share your feedback! Did you find this helpful?
Comprehensive health, vision, & dental plans
Family planning, support, & leave for parents
Mental healthcare
Student loan assistance
Volunteer time off
Dog friendly office
23andMe, a leader in genetic testing, has recently announced an update to its African American Community feature, a move that has been hailed as a significant step forward in genetic research and heritage exploration.
TTAM Commits to Comply with Company’s Privacy Policy and All Applicable Laws TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data and Privacy No Changes to 23andMe’s Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered into a definitive agreement with TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and led by 23andMe Co-Founder and former CEO Anne Wojcicki, for the sale of substantially all of the Company’s assets, including the Personal Genome Service (PGS) and Research Services business lines and the Lemonaid Health business, for a purchase price of $305 million. The agreement with TTAM is the result of a final round of bidding that occurred earlier today between TTAM and Regeneron Pharmaceuticals, Inc. (“Regeneron”) (NASDAQ: REGN). The final round of bidding was conducted according to procedures approved by the U.S. Bankruptcy Court for the Eastern District of Missouri (the “Court") and designed to allow the Special Committee of 23andMe’s Board of Directors to obtain, consistent with its fiduciary duties, the most value-maximizing transaction for the Company’s stakeholders
Regeneron Pharmaceuticals is seeking to buy 23andMe and said it would honor all existing consents, privacy policies and statements, terms of services and notices.
23andMe has secured a new funding round of $305 million, led by its former CEO. The investment aims to advance the company's mission of empowering individuals with genetic information, likely supporting research, service expansion, and growth in personal genomics. The article highlights investor confidence in 23andMe's approach but lacks details on the investment round type and other investors.
Bankrupt genetic testing company 23andMe is seeking new bids following a $305 million offer from co-founder Anne Wojcicki, who has secured backing from an...